2005 © Oxford University Press
Preservation of Fertility and Ovarian Function and Minimization of Chemotherapy-Induced Gonadotoxicity in Young Women by GnRH-a
Affiliation of authors: Reproductive Endocrinology, Rambam Medical Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 31096
Correspondence to: Zeev Blumenfeld, MD, Reproductive Endocrinology and Infertility Section, Department of Obstetrics and Gynecology, Technion-Faculty of Medicine, Rambam Medical Center, Haifa 31096 Israel (e-mail: bzeev{at}techunix.technion.ac.il).
Improved long-term survival in young women with lymphoma and leukemia has increased attention to the preservation of their future fertility. We have attempted to minimize the gonadotoxic effect of chemotherapy by cotreatment with a GnRH agonist analog, inducing a temporary prepubertal milieu. Our prospective clinical case series includes 92 women with lymphoma, aged 1540 years, 10 with leukemia and 18 undergoing chemotherapeutic treatments for nonmalignant autoimmune diseases. Depot D-TRP6-GnRH-a was injected monthly from before the initiation of chemotherapy until its conclusion, for up to 6 months. We used 82 similarly treated patients with lymphoma not given GnRH-a as a comparison group. All but five of the surviving evaluable patients with GnRH-a/chemotherapy cotreatment resumed spontaneous ovulation and menses or conceived, whereas 53% of the patients in the comparison group experienced premature ovarian failure (P<.01). Mechanisms to explain this apparent chemoprotective effect are discussed, and the work of other investigators in this area is reviewed.
This article has been cited by other articles:
![]() |
R. Beck-Fruchter, A. Weiss, and E. Shalev GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data Hum. Reprod. Update, November 1, 2008; 14(6): 553 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Demeestere, P. Simon, S. Emiliani, A. Delbaere, and Y. Englert Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin's Disease Oncologist, December 1, 2007; 12(12): 1437 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vernaeve, D. Bodri, M. Colodron, R. Vidal, M. Durban, and O. Coll Endometrial receptivity after oocyte donation in recipients with a history of chemotherapy and/or radiotherapy Hum. Reprod., November 1, 2007; 22(11): 2863 - 2867. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Blumenfeld How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries Oncologist, September 1, 2007; 12(9): 1044 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Blumenfeld, M. B. Arush, and T. Zuckerman Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment Hum. Reprod., August 1, 2007; 22(8): 2346 - 2346. [Full Text] [PDF] |
||||


